This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

5 Dow Dividend Stocks to Beat the S&P


Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

Along with the rest of the pharmaceutical industry, Merck ( MRK) is having a good year in 2013. Shares of the $143 billion big pharma company have rallied more than 16% year-to-date, besting the S&P 500's impressive performance by about 100 basis points. Then, tack on a 3.61% dividend yield to the equation.

>>5 Summer Buy Signals From the Health Care Sector

Merck has been busy in recent years. While the guillotine of patent drop-offs has been edging closer and closer to big pharma's neck, Merck has been hard at work adding attractive new products to its pipeline -- and bringing them to market. While the firm already lost patent protection on its blockbuster asthma drug Singulair in August 2012, the loss is being offset by newcomers such as diabetes drug Januvia and HPV vaccine Gardasil. Merck is considerably U.S.-biased; the firm still earns half of its revenues stateside, a fact that should get a boost from healthcare initiatives that increase access to pharmaceuticals.

With a net cash and investment position of almost $8 billion, Merck has the wherewithal to keep on building its pipeline without turning to the capital markets. The firm's hefty net margins should keep those coffers stuffed in 2013 and beyond.
5 of 6

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
DD $63.76 0.14%
INTC $29.72 -0.60%
MRK $53.40 -1.30%
T $38.66 -0.19%
VZ $50.80 -0.09%


Chart of I:DJI
DOW 17,590.58 -70.13 -0.40%
S&P 500 2,042.16 -8.47 -0.41%
NASDAQ 4,689.8610 -27.2330 -0.58%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs